Metabolic & Incretin Research Guide

Retatrutide: Mechanism, Handling & Research Guide

Also known as: LY3437943, GLP3-R, triple-G agonist

Key Facts

Retatrutide is a metabolic & incretin research peptide (C223H343F3N46O70, MW 4731.33 g/mol). Triple-agonist research peptide targeting GIP, GLP-1, and glucagon receptors for advanced metabolic studies. It is supplied as a lyophilized powder for laboratory and in-vitro research use only — not for human consumption.

Classification	GIP / GLP-1 / glucagon triple-receptor agonist
Molecular Formula	C223H343F3N46O70
Molecular Weight	4731.33 g/mol
CAS Number	2381089-83-2
Research Half-Life	~6 days
Form	Lyophilized powder
Research Category	Metabolic & Incretin

What is Retatrutide?

Retatrutide is a first-in-class triple-agonist peptide that simultaneously activates glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. Its mechanism of action involves binding all three receptor systems to modulate appetite signaling, glucose homeostasis, and energy expenditure through complementary metabolic pathways. The glucagon receptor component is believed to contribute additional energy expenditure and hepatic lipid metabolism benefits not seen with GLP-1-only or GIP/GLP-1 dual agonists. Compared to semaglutide (GLP-1 only) and tirzepatide (GIP/GLP-1 dual), retatrutide represents an expansion of the incretin-based approach by incorporating glucagon receptor activation, which studies suggest modulates thermogenesis and fat oxidation. For research use, the lyophilized powder should be stored at -20C and reconstituted with bacteriostatic water immediately before use; reconstituted solutions remain stable under refrigeration at 2-8C for up to 28 days. This compound is primarily investigated by academic metabolic research centers, pharmaceutical R&D divisions, and endocrinology laboratories studying multi-receptor agonism as a strategy for metabolic syndrome research.

Retatrutide Research Applications

In published and preclinical research, Retatrutide has been studied across the following areas:

GIP/GLP-1/Glucagon receptor agonist research
Metabolic-pathway research
Glucose regulation and insulin sensitivity
Metabolic and GH-axis research

Retatrutide in Research: Study Context

In laboratory research the lyophilized peptide is reconstituted with bacteriostatic water to a defined mg/mL concentration; the assay or model dictates the working concentration, and there is no human concentration because retatrutide is not FDA-approved. Researchers should reference the primary trial literature for study design and document the exact lot COA.

How Retatrutide Compares

Researchers frequently evaluate Retatrutide alongside related compounds:

Retatrutide vs Tirzepatide — dual GIP/GLP-1 vs. triple agonist

Retatrutide — Frequently Asked Questions

What makes retatrutide different from tirzepatide?

Retatrutide activates three receptors — GIP, GLP-1, and glucagon — while tirzepatide activates two (GIP and GLP-1). The added glucagon-receptor activity is the focus of much of the comparative research interest.

Is Retatrutide legal to buy for research?

Retatrutide is sold in the United States as a research chemical for laboratory and in-vitro use only. It is not approved by the FDA for human use and is not sold for human consumption. Researchers are responsible for compliance with all applicable federal, state, and institutional regulations.

Does Retatrutide come with a Certificate of Analysis?

Yes. Every batch of Retatrutide from Elyte Peptides ships with a third-party Certificate of Analysis (COA) documenting identity and HPLC purity (≥98%), so research results can be traced to a verified lot.

What is GLP3-R (Retatrutide) and how does it work?

Retatrutide is a triple-agonist peptide that simultaneously targets GIP, GLP-1, and glucagon receptors. Unlike single- or dual-agonist compounds, retatrutide activates all three incretin and glucagon pathways, which in preclinical models has been observed to influence glucose homeostasis, energy expenditure, and lipid metabolism through complementary mechanisms. This tri-receptor engagement represents a novel approach in metabolic research.

What research has been done on GLP3-R (Retatrutide)?

Preclinical studies have also explored its effects on hepatic lipid content, with researchers observing reductions in liver fat in animal models. Additional investigations are examining its potential role in non-alcoholic steatohepatitis (NASH) and cardiovascular biomarkers.

How does Retatrutide compare to Semaglutide or Tirzepatide?

While semaglutide acts solely on the GLP-1 receptor and tirzepatide targets both GIP and GLP-1 receptors, retatrutide adds a third mechanism through glucagon receptor agonism. In research settings, this triple-agonist approach has been associated with greater effects on energy expenditure and lipid oxidation compared to single- or dual-agonist peptides. Each compound occupies a distinct pharmacological profile for comparative metabolic research.

Research References

All research guides